Paul Jost
Infectious Disease · Kansas City, MONPI 1720018716
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.6% of the total across 358 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations.
Across 358 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1K
- Viiv Healthcare Company$998
- Gilead$688
- Johnson & Johnson$604
- Insmed, Inc.$527
- Melinta Therapeutics, LLC$499
- plus $2K from 21 others
What the payments were for
- Speaking & faculty fees$2023%
- Food & beverage$5,85291%
- Education$4086%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 64 | $1,166 |
| Viiv Healthcare Company | 62 | $998 |
| Gilead | 45 | $688 |
| Johnson & Johnson | 35 | $604 |
| Insmed, Inc. | 24 | $527 |
| Melinta Therapeutics, LLC | 32 | $499 |
| AbbVie(2 entities) | 22 | $414 |
| Napo Pharmaceuticals Inc | 15 | $296 |
| La Jolla Pharmaceutical Company | 13 | $209 |
| Mayne Pharma Commercial LLC | 7 | $161 |
| Astellas Pharma US Inc | 4 | $161 |
| Shionogi Inc | 4 | $111 |
| Shire North American Group Inc | 7 | $109 |
| Janssen Products, LP | 1 | $99 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $82 |
| Theratechnologies Inc. | 5 | $82 |
| Vyera Pharmaceuticals, LLC | 2 | $40 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $35 |
| Nabriva Therapeutics, PLC | 2 | $34 |
| Mylan Institutional Inc. | 1 | $26 |
| Octapharma USA, Inc. | 1 | $25 |
| Grifols USA, LLC | 1 | $20 |
| Pfizer | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| ADMA Biomanufacturing LLC | 1 | $13 |
How this compares
$6,462 in reported general payments places this provider in the 85th percentile of 177 infectious disease providers in Missouri.
Other infectious disease in Kansas City
- Joseph BrewerKansas City$7K
- Muna AbuerreishKansas City$3K
- Arundhati DesaiKansas City$3K
- David McKinseyKansas City$796
- Robert BelsheSaint Louis$382K
- Erik DubberkeSaint Louis$144K
- Rupa PatelSaint Louis$96K
- Michael DiamondSaint Louis$44K
- Nirmol PhilipChesterfield$31K
- Andrej SpecSaint Louis$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.